Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Coronary Artery Disease: HELP
Articles from Quebec
Based on 344 articles published since 2009
||||

These are the 344 published articles about Coronary Artery Disease that originated from Quebec during 2009-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14
1 Guideline Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. 2018

Angiolillo, Dominick J / Goodman, Shaun G / Bhatt, Deepak L / Eikelboom, John W / Price, Matthew J / Moliterno, David J / Cannon, Christopher P / Tanguay, Jean-Francois / Granger, Christopher B / Mauri, Laura / Holmes, David R / Gibson, C Michael / Faxon, David P. ·Division of Cardiology, University of Florida College of Medicine-Jacksonville (D.J.A.). · St. Michael's Hospital, University of Toronto, and the Canadian Heart Research Centre, Canada (S.G.G.). · Canadian Virtual Coordinating Centre for Global Collaborative Cardiovascular Research Centre, University of Alberta, Canada (S.G.G.). · Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B., C.P.C., L.M., D.P.F.). · Department of Medicine, Population Health Research Institute, Thrombosis & Atherosclerosis Research Institute, Hamilton, Canada (J.W.E.). · Division of Cardiovascular Diseases, Scripps Clinic, La Jolla, CA (M.J.P.). · Division of Cardiovascular Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.). · Department of Medicine, Montreal Heart Institute, Université de Montréal, Canada (J.-F.T.). · Duke Clinical Research Institute, Duke University, Durham, NC (C.B.G.). · Mayo Clinic, Rochester, MN (D.R.H.). · Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.). ·Circulation · Pubmed #30571525.

ABSTRACT: The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation represents a challenge in clinical practice. In 2016, an updated opinion of selected experts from the United States and Canada on the treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention was reported. After the 2016 North American consensus statement on the management of antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, results of pivotal clinical trials assessing the type of oral anticoagulant agent and the duration of antiplatelet treatment have been published. On the basis of these results, this focused update on the antithrombotic management of patients with atrial fibrillation undergoing percutaneous coronary intervention recommends that a non-vitamin K antagonist oral anticoagulant be preferred over a vitamin K antagonist as the oral anticoagulant of choice. Moreover, a double-therapy regimen (oral anticoagulant plus single antiplatelet therapy with a P2Y

2 Guideline Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018. 2018

Brunham, Liam R / Ruel, Isabelle / Aljenedil, Sumayah / Rivière, Jean-Baptiste / Baass, Alexis / Tu, Jack V / Mancini, G B John / Raggi, Paolo / Gupta, Milan / Couture, Patrick / Pearson, Glen J / Bergeron, Jean / Francis, Gordon A / McCrindle, Brian W / Morrison, Katherine / St-Pierre, Julie / Henderson, Mélanie / Hegele, Robert A / Genest, Jacques / Goguen, Jeannette / Gaudet, Daniel / Paré, Guillaume / Romney, Jacques / Ransom, Thomas / Bernard, Sophie / Katz, Pamela / Joy, Tisha R / Bewick, David / Brophy, James. ·Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: Liam.brunham@ubc.ca. · Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montréal, Quebec, Canada. · Department of Medicine, McGill University, Montréal, Quebec, Canada; Nutrition, Metabolism and Atherosclerosis Clinic, Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada. · Faculty of Medicine, University of Toronto, Institute for Clinical Evaluative Sciences, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. · Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada. · Department of Medicine, McMaster University, Hamilton, and Canadian Collaborative Research Network, Brampton, Ontario, Canada. · Departments of Medicine and Laboratory Medicine, CHU de Québec-Université Laval, Québec City, Quebec, Canada. · Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada. · Department of Pediatrics, The Labatt Family Heart Centre, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. · Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada. · Department of Pediatrics, McGill University, Clinique 180, Montréal, Quebec, Canada. · Department of Pediatrics, Université de Montréal, CHU Sainte-Justine, Montréal, Quebec, Canada. · Departments of Medicine and Biochemistry, Schulich School of Medicine and Robarts Research Institute, Western University, London, Ontario, Canada. · Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montréal, Quebec, Canada; Department of Medicine, McGill University, Montréal, Quebec, Canada. · Department of Medicine, University of Toronto and Division of Endocrinology, St Michael's Hospital, Toronto Ontario, Canada. · Lipidology Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, Saguenay, Quebec, Canada. · Department of Pathology and Molecular Medicine, Department of Clinical Epidemiology and Biostatistics, Population Health Research Institute and Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, Ontario, Canada. · Division of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada. · Nutrition, Metabolism and Atherosclerosis Clinic, Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada; Department of Medicine, Division of Endocrinology, Université de Montreal, Montréal, Quebec, Canada. · Department of Medicine, Section of Endocrinology and Metabolism, University of Manitoba, St Boniface Hospital, Winnipeg, Manitoba, Canada. · Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada. · Division of Cardiology, Department of Medicine, Dalhousie University, St John, New Brunswick, Canada. ·Can J Cardiol · Pubmed #30527143.

ABSTRACT: Familial hypercholesterolemia (FH) is the most common monogenic disorder causing premature atherosclerotic cardiovascular disease. It affects 1 in 250 individuals worldwide, and of the approximately 145,000 Canadians estimated to have FH, most are undiagnosed. Herein, we provide an update of the 2014 Canadian Cardiovascular Society position statement on FH addressing the need for case identification, prompt recognition, and treatment with statins and ezetimibe, and cascade family screening. We provide a new Canadian definition for FH and tools for clinicians to make a diagnosis. The risk of atherosclerotic cardiovascular disease in patients with "definite" FH is 10- to 20-fold that of a normolipidemic individual and initiating treatment in youth or young adulthood can normalize life expectancy. Target levels for low-density lipoprotein cholesterol are proposed and are aligned with the Canadian Cardiovascular Society guidelines on dyslipidemia. Recommendation for the use of inhibitors of proprotein convertase kexin/subtilisin type 9 are made in patients who cannot achieve therapeutic low-density lipoprotein cholesterol targets on maximally tolerated statins and ezetimibe. The writing committee used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology in the preparation of the present document, which offers guidance for practical evaluation and management of patients with FH. This position statement also aims to raise awareness of FH nationally, and to mobilize patient support, promote knowledge translation, and availability of treatment and health care resources for this under-recognized, but important medical condition.

3 Guideline 2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. 2018

Andrade, Jason G / Verma, Atul / Mitchell, L Brent / Parkash, Ratika / Leblanc, Kori / Atzema, Clare / Healey, Jeff S / Bell, Alan / Cairns, John / Connolly, Stuart / Cox, Jafna / Dorian, Paul / Gladstone, David / McMurtry, M Sean / Nair, Girish M / Pilote, Louise / Sarrazin, Jean-Francois / Sharma, Mike / Skanes, Allan / Talajic, Mario / Tsang, Teresa / Verma, Subodh / Wyse, D George / Nattel, Stanley / Macle, Laurent / Anonymous5291340. ·University of British Columbia, Vancouver, British Columbia, Canada; Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. · Southlake Regional Health Centre, Newmarket, Ontario, Canada. · Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Alberta, Canada. · QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada. · University Health Network, University of Toronto, Toronto, Ontario, Canada. · Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada. · McMaster University, Hamilton, Ontario, Canada; Hamilton General Hospital, Hamilton, Ontario, Canada. · University of Toronto, Toronto, Ontario, Canada. · University of British Columbia, Vancouver, British Columbia, Canada. · St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · University of Alberta, Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada. · University of Ottawa Heart Institute, Ottawa, Ontario, Canada. · McGill University Health Centre, Montréal, Quebec, Canada. · Institut universitaire de cardiologie et pneumologie, Quebec, Quebec, Canada. · London Heart Institute, Western University, London, Ontario, Canada. · Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. · Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. Electronic address: lmacle@mac.com. ·Can J Cardiol · Pubmed #30404743.

ABSTRACT: The Canadian Cardiovascular Society (CCS) Atrial Fibrillation Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in atrial fibrillation (AF) management. This 2018 Focused Update addresses: (1) anticoagulation in the context of cardioversion of AF; (2) the management of antithrombotic therapy for patients with AF in the context of coronary artery disease; (3) investigation and management of subclinical AF; (4) the use of antidotes for the reversal of non-vitamin K antagonist oral anticoagulants; (5) acute pharmacological cardioversion of AF; (6) catheter ablation for AF, including patients with concomitant AF and heart failure; and (7) an integrated approach to the patient with AF and modifiable cardiovascular risk factors. The recommendations were developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) standards. Individual studies and literature were reviewed for quality and bias; the literature review process and evidence tables are included as Supplementary Material and are available on the CCS Web site. Details of the updated recommendations are presented, along with their background and rationale. This document is linked to an updated summary of all CCS AF guidelines recommendations, from 2010 to the present 2018 Focused Update, which is provided in the Supplementary Material.

4 Guideline Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update. 2016

Angiolillo, Dominick J / Goodman, Shaun G / Bhatt, Deepak L / Eikelboom, John W / Price, Matthew J / Moliterno, David J / Cannon, Christopher P / Tanguay, Jean-Francois / Granger, Christopher B / Mauri, Laura / Holmes, David R / Gibson, C Michael / Faxon, David P. ·From the Division of Cardiology, University of Florida College of Medicine-Jacksonville (D.J.A.) · St Michael's Hospital, University of Toronto, and the Canadian Heart Research Centre · Canadian VIGOUR Centre, University of Alberta, Edmonton (S.G.G.) · Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B., D.P.F.) · Department of Medicine, Population Health Research Institute, Thrombosis & Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E.) · Division of Cardiovascular Diseases, Scripps Clinic, La Jolla CA (M.J.P.) · Division of Cardiovascular Medicine and Gill Heart Institute, University of Kentucky, Lexington (D.J.M.) · Brigham and Women's Hospital, Harvard Clinical Research Institute, Harvard Medical School, Boston, MA (C.P.C., L.M.) · Department of Medicine, Montreal Heart Institute, Université de Montréal, QC, Canada (J.-F.T.) · Duke Clinical Research Institute, Duke University, Durham, NC (C.B.G.) · Mayo Clinic, Rochester, MN (D.R.H.) · and Division of Cardiology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA (C.M.G.). ·Circ Cardiovasc Interv · Pubmed #27803042.

ABSTRACT: The optimal antithrombotic treatment regimen for patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation is an emerging clinical problem. Currently, there is limited evidenced-based data on the optimal antithrombotic treatment regimen, including antiplatelet and anticoagulant therapies, for these high-risk patients with practice guidelines, thus, providing limited recommendations. Over the past years, expert consensus documents have provided guidance to clinicians on how to manage patients with atrial fibrillation undergoing percutaneous coronary intervention. Given the recent advancements in the field, the current document provides an updated opinion of selected North American experts from the United States and Canada on the treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention. In particular, this document provides the current views on (1) embolic/stroke risk, (2) ischemic/thrombotic cardiac risk, and (3) bleeding risk, which are pivotal for discerning the choice of antithrombotic therapy. In addition, we describe the recent advances in pharmacology, stent designs, and clinical trials relevant to the field. Ultimately, we provide expert consensus-derived recommendations, using a pragmatic approach, on the management of patients with atrial fibrillation undergoing percutaneous coronary intervention.

5 Guideline 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. 2016

Macle, Laurent / Cairns, John / Leblanc, Kori / Tsang, Teresa / Skanes, Allan / Cox, Jafna L / Healey, Jeff S / Bell, Alan / Pilote, Louise / Andrade, Jason G / Mitchell, L Brent / Atzema, Clare / Gladstone, David / Sharma, Mike / Verma, Subodh / Connolly, Stuart / Dorian, Paul / Parkash, Ratika / Talajic, Mario / Nattel, Stanley / Verma, Atul / Anonymous6140880. ·Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. Electronic address: lmacle@mac.com. · University of British Columbia, Vancouver, British Columbia, Canada. · University Health Network, University of Toronto, Toronto, Ontario, Canada. · London Heart Institute, Western University, London, Ontario, Canada. · QEII Health Sciences Centre, Dalhousie University, Halifax, Nova Scotia, Canada. · McMaster University and Hamilton General Hospital, Hamilton, Ontario, Canada. · University of Toronto, Toronto, Ontario, Canada. · McGill University Health Centre, Montréal, Québec, Canada. · Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada. · Libin Cardiovascular Institute of Alberta, University of Calgary, and Alberta Health Services, Calgary, Alberta, Canada. · Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ontario, Canada. · McMaster University and Hamilton General Hospital, Hamilton, Ontario, Canada; The Canadian Stroke Network, Ottawa, Ontario, Canada. · St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · Southlake Regional Health Centre, Newmarket, Ontario, Canada. ·Can J Cardiol · Pubmed #27609430.

ABSTRACT: The Canadian Cardiovascular Society (CCS) Atrial Fibrillation (AF) Guidelines Committee provides periodic reviews of new data to produce focused updates that address clinically important advances in AF management. This 2016 Focused Update deals with: (1) the management of antithrombotic therapy for AF patients in the context of the various clinical presentations of coronary artery disease; (2) real-life data with non-vitamin K antagonist oral anticoagulants; (3) the use of antidotes for the reversal of non-vitamin K antagonist oral anticoagulants; (4) digoxin as a rate control agent; (5) perioperative anticoagulation management; and (6) AF surgical therapy including the prevention and treatment of AF after cardiac surgery. The recommendations were developed with the same methodology used for the initial 2010 guidelines and the 2012 and 2014 Focused Updates. Using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) standards, individual studies and literature were reviewed for quality and bias; the literature review process and evidence tables are included in the Supplementary Material, and on the CCS Web site. The section on concomitant AF and coronary artery disease was developed in collaboration with the CCS Antiplatelet Guidelines Committee. Details of the updated recommendations are presented, along with their background and rationale. This document is linked to an updated summary of all CCS AF Guidelines recommendations, from 2010 to the present 2016 Focused Update.

6 Guideline Canadian Cardiovascular Society guidelines for the diagnosis and management of stable ischemic heart disease. 2014

Mancini, G B John / Gosselin, Gilbert / Chow, Benjamin / Kostuk, William / Stone, James / Yvorchuk, Kenneth J / Abramson, Beth L / Cartier, Raymond / Huckell, Victor / Tardif, Jean-Claude / Connelly, Kim / Ducas, John / Farkouh, Michael E / Gupta, Milan / Juneau, Martin / O'Neill, Blair / Raggi, Paolo / Teo, Koon / Verma, Subodh / Zimmermann, Rodney / Anonymous3830801. ·Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: mancini@mail.ubc.ca. · Department of Medicine, Montreal Heart Institute, University of Montreal, Montréal, Québec, Canada. · Department of Medicine, Ottawa Heart Institute, Ottawa, Ontario, Canada. · Department of Medicine, University of Western Ontario, London, Ontario, Canada. · Department of Medicine, University of Calgary, Calgary, Alberta, Canada. · Vancouver Island Health Authority, Victoria, British Columbia, Canada. · Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. · Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. · Department of Medicine, University Health Network Hospitals, University of Toronto, Toronto, Onario, Canada. · Department of Medicine, McMaster University, Hamilton, Ontario, Canada. · Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Department of Medicine, Regina Qu'Appelle Health Region, University of Saskatchewan, Regina, Saskatchewan, Canada. ·Can J Cardiol · Pubmed #25064578.

ABSTRACT: This overview provides a guideline for the management of stable ischemic heart disease. It represents the work of a primary and secondary panel of participants from across Canada who achieved consensus on behalf of the Canadian Cardiovascular Society. The suggestions and recommendations are intended to be of relevance to primary care and specialist physicians with an emphasis on rational deployment of diagnostic tests, expedited implementation of long- and short-term medical therapy, timely consideration of revascularization, and practical follow-up measures.

7 Guideline Canadian Cardiovascular Society position statement on the management of thoracic aortic disease. 2014

Boodhwani, Munir / Andelfinger, Gregor / Leipsic, Jonathon / Lindsay, Thomas / McMurtry, M Sean / Therrien, Judith / Siu, Samuel C / Anonymous6800795. ·Division of Cardiac Surgery, University of Ottawa Heart Institute, Ottawa, Ontario, Canada. Electronic address: mboodhwani@ottawaheart.ca. · Department of Pediatrics, University of Montreal, Montreal, Québec, Canada. · Department of Radiology, University of British Colombia, Vancouver, British Colombia, Canada. · Division of Vascular Surgery, University Health Network, Toronto, Ontario, Canada. · Division of Cardiology, University of Alberta, Edmonton, Alberta, Canada. · Division of Cardiology, McGill University, Montreal, Québec, Canada. · Division of Cardiology, Western University, London, Ontario, Canada. ·Can J Cardiol · Pubmed #24882528.

ABSTRACT: This Canadian Cardiovascular Society position statement aims to provide succinct perspectives on key issues in the management of thoracic aortic disease (TAD). This document is not a comprehensive overview of TAD and important elements of the epidemiology, presentation, diagnosis, and management of acute aortic syndromes are deliberately not discussed; readers are referred to the 2010 guidelines published by the American Heart Association, American College of Cardiology, American Association for Thoracic Surgery, and other stakeholders. Rather, this document is a practical guide for clinicians managing adult patients with TAD. Topics covered include size thresholds for surgical intervention, emerging therapies, imaging modalities, medical and lifestyle management, and genetics of TAD. The primary panel consisted of experts from a variety of disciplines that are essential for comprehensive management of TAD patients. The methodology involved a focused literature review with an emphasis on updates since 2010 and the use of Grading of Recommendations Assessment, Development, and Evaluation methodology to arrive at specific recommendations. The final document then underwent review by a secondary panel. This document aims to provide recommendations for most patients and situations. However, the ultimate judgement regarding the management of any individual patients should be made by their health care team.

8 Editorial Closing congenital vascular connections: the novel and the traditional… both at risk of developing ventricular dysfunction? 2018

Martucci, Giuseppe Joe / Piazza, Nicolo / Dancea, Adrian. ·Royal Victoria Hospital, McGill University Health Center, McGill University, Montreal, Quebec, Canada. ·EuroIntervention · Pubmed #29624173.

ABSTRACT: -- No abstract --

9 Editorial The Importance of Sex in the Stress-Heart Disease Relationship and the Potential Contribution of Gender to Future Research. 2018

Bacon, Simon L. ·From the Montreal Behavioural Medicine Centre, CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal, Quebec, Canada; and Department of Exercise Science, Concordia University, Montreal, Quebec, Canada. simon.bacon@concordia.ca. ·Arterioscler Thromb Vasc Biol · Pubmed #29367230.

ABSTRACT: -- No abstract --

10 Editorial Combining Transcatheter Aortic Valve Replacement and Coronary Angiography/Percutaneous Coronary Intervention Procedures: Ready for Prime Time? 2017

Rodés-Cabau, Josep. ·From the Quebec Heart and Lung Institute, Laval University, Quebec City, Canada. josep.rodes@criucpq.ulaval.ca. ·Circ Cardiovasc Interv · Pubmed #28768761.

ABSTRACT: -- No abstract --

11 Editorial Management of coronary artery disease with cardiac CT beyond gatekeeping. 2017

Cademartiri, Filippo / Nistri, Stefano / Tarantini, Giuseppe / Maffei, Erica. ·Department of Radiology & Research Center, Montreal Heart Institute/Universitè de Montreal, Montreal, Quebec, Canada. · Department of Radiology, Erasmus Medical Center University, Rotterdam, The Netherlands. · Cardiology Service, CMSR- Veneto Medica, Altavilla Vicentina, Italy. · Department of Cardiology, University of Padua, Padua, Italy. ·Heart · Pubmed #28446549.

ABSTRACT: -- No abstract --

12 Editorial ANGPTL3: A Gene, a Protein, a New Target? Aye, There's the Rub! 2017

Genest, Jacques. ·Research Institute of the McGill University Health Center, Montreal, Québec, Canada. Electronic address: jacques.genest@mcgill.ca. ·J Am Coll Cardiol · Pubmed #28385497.

ABSTRACT: -- No abstract --

13 Editorial Cardiac CT for the detection of vulnerable plaque. 2016

Cademartiri, Filippo / Maffei, Erica. ·Department of Radiology, Montreal Heart Institute, Universitè de Montreal, Montreal, Canada Department of Radiology, Erasmus Medical Center University, Rotterdam, The Netherlands filippocademartiri@gmail.com. · Centre de Recherche, Montreal Heart Institute, Universitè de Montreal, Montreal, Canada. ·Eur Heart J Cardiovasc Imaging · Pubmed #26628618.

ABSTRACT: -- No abstract --

14 Editorial Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. 2014

Knowles, Joshua W / O'Brien, Emily C / Greendale, Karen / Wilemon, Katherine / Genest, Jacques / Sperling, Laurence S / Neal, William A / Rader, Daniel J / Khoury, Muin J. ·Stanford University School of Medicine and Cardiovascular Institute, Stanford, CA; The FH Foundation, South Pasadena, CA. · Duke Clinical Research Institute, Durham, NC. Electronic address: emily.obrien@duke.edu. · The FH Foundation, South Pasadena, CA. · McGill University, Montreal, Canada. · Emory University School of Medicine, Atlanta, GA. · West Virginia University, Morgantown, WV. · University of Pennsylvania, Philadelphia, PA. · Office of Public Health Genomics, Centers for Disease Control & Prevention, Atlanta, GA. ·Am Heart J · Pubmed #25458642.

ABSTRACT: Familial hypercholesterolemia (FH) is a genetic disease characterized by substantial elevations of low-density lipoprotein cholesterol, unrelated to diet or lifestyle. Untreated FH patients have 20 times the risk of developing coronary artery disease, compared with the general population. Estimates indicate that as many as 1 in 500 people of all ethnicities and 1 in 250 people of Northern European descent may have FH; nevertheless, the condition remains largely undiagnosed. In the United States alone, perhaps as little as 1% of FH patients have been diagnosed. Consequently, there are potentially millions of children and adults worldwide who are unaware that they have a life-threatening condition. In countries like the Netherlands, the United Kingdom, and Spain, cascade screening programs have led to dramatic improvements in FH case identification. Given that there are currently no systematic approaches in the United States to identify FH patients or affected relatives, the patient-centric nonprofit FH Foundation convened a national FH Summit in 2013, where participants issued a "call to action" to health care providers, professional organizations, public health programs, patient advocacy groups, and FH experts, in order to bring greater attention to this potentially deadly, but (with proper diagnosis) eminently treatable, condition.

15 Editorial Should early post-stress imaging be performed on a routine clinical basis for myocardial perfusion studies? 2014

Taillefer, Raymond. ·Department of Radiology, Radio-Oncology and Nuclear Medicine, Université de Montréal, Montreal, QC, Canada, rtaillefer@hotmail.com. ·J Nucl Cardiol · Pubmed #25213202.

ABSTRACT: -- No abstract --

16 Editorial Vitamin C and percutaneous coronary intervention: some answers, more questions. 2014

Gebhard, Catherine / Tardif, Jean-Claude. ·Montreal Heart Institute, Montreal, Québec, Canada. · Montreal Heart Institute, Montreal, Québec, Canada; Department of Medicine, Université de Montréal, Montreal, Québec, Canada. Electronic address: jean-claude.tardif@icm-mhi.org. ·Can J Cardiol · Pubmed #24365188.

ABSTRACT: -- No abstract --

17 Editorial Near-infrared spectroscopy for cardiovascular risk assessment? Not ready for prime time. 2014

Gebhard, Catherine / L'Allier, Philippe L / Tardif, Jean-Claude. ·Montreal Heart Institute, Montreal, Canada. ·Eur Heart J · Pubmed #24052602.

ABSTRACT: -- No abstract --

18 Editorial Depression screening in patients with coronary heart disease: does the evidence matter? 2013

Thombs, Brett D / Ziegelstein, Roy C. ·Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec, Canada; Department of Psychiatry, McGill University, Montréal, Quebec, Canada; Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montréal, Quebec, Canada; Department of Medicine, McGill University, Montréal, Quebec, Canada; Department of Educational and Counselling Psychology, McGill University, Montréal, Quebec, Canada; Department of Psychology, McGill University, Montréal, Quebec, Canada; School of Nursing, McGill University, Montréal, Quebec, Canada. Electronic address: brett.thombs@mcgill.ca. ·J Psychosom Res · Pubmed #24290037.

ABSTRACT: -- No abstract --

19 Review Molecular imaging of coronary inflammation. 2019

Pelletier-Galarneau, Matthieu / Ruddy, Terrence D. ·Department of Radiology and Nuclear Medicine, Institut de cardiologie de Montréal, Université de Montréal, Montréal, Québec, Canada; Gordon Center for Medical Imaging, Massachusetts General Hospital, Boston, MA, USA. · Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4W7, Canada. Electronic address: truddy@ottawaheart.ca. ·Trends Cardiovasc Med · Pubmed #30195945.

ABSTRACT: Coronary inflammation is related to atherosclerotic disease and, less frequently, systemic vasculitis. Regardless of the etiology, coronary inflammation is associated with adverse cardiac events. Molecular imaging with

20 Review Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease Demystified. 2018

Andrade, Jason G / Deyell, Marc W / Wong, Graham C / Macle, Laurent. ·Montréal Heart Institute, Department of Medicine, Université de Montréal, Québec, Canada; Heart Rhythm Services, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: Jason.andrade@vch.ca. · Heart Rhythm Services, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. · University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada. · Montréal Heart Institute, Department of Medicine, Université de Montréal, Québec, Canada. ·Can J Cardiol · Pubmed #30404748.

ABSTRACT: Atrial fibrillation (AF) is a progressive chronic disease characterized by exacerbations and periods of remission. It is estimated that up to 20% to 30% of those with AF also have coronary artery disease (CAD), and 5% to 15% will require percutaneous coronary intervention (PCI). In patients with concomitant AF and CAD, management remains challenging and requires a careful and balanced assessment of the risk of bleeding against the anticipated impact on ischemic outcomes (AF-related stroke and systemic embolism, as well as ischemic coronary events). Oral anticoagulation (OAC) is indicated for the prevention of AF-related stroke and systemic embolism, whereas antiplatelet therapy is indicated for the prevention of coronary events. Each offers a relative efficacy benefit (dual antiplatelet therapy [DAPT] is more effective than OAC alone in reducing cardiovascular death, myocardial infarction, stent thrombosis, and ischemic coronary events in a population with acute coronary syndromes [ACS]), but with a relative compromise (DAPT is significantly inferior to OAC for the prevention of stroke/systemic embolism in an AF population at increased risk of stroke). The purpose of this review is to explore the current evidence and rationale for antithrombotic treatment strategies in patients with both AF and CAD. Specifically, there is a focus on how to best tailor the therapeutic choices (OAC and antiplatelet therapy) to individual patients based on their underlying coronary presentation.

21 Review Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis. 2018

Khan, Razi / Rheaume, Eric / Tardif, Jean-Claude. ·Royal Columbian Hospital, 330 E Columbia St., New Westminster, BC, V3L 3W7, Canada. razi.khan@gmail.com. · Montreal Heart Institute, Montreal, QC, H1T 1C8, Canada. ·Curr Atheroscler Rep · Pubmed #30219977.

ABSTRACT: PURPOSE: The purpose of this review was to examine the role of IL-1β in the inflammatory process central to the development of atherosclerosis and to discuss current clinical evidence for treatments targeting IL-1β in coronary artery disease. RECENT FINDINGS: IL-1β has been shown to modulate atherosclerotic plaque progression by upregulating the synthesis of adhesion molecules on endothelial cells, as well increasing activation and proliferation of vascular smooth muscle cells. Animal studies have further suggested that alterations in the balance between agonists and antagonists of IL-1β are important in promoting atherosclerosis. In humans, preliminary assessment of therapy targeting IL-1β noted early reductions in serum inflammatory biomarkers among those with systemic inflammatory or coronary artery disease. The CANTOS trial, a large randomized double-blind study found that canakinumab, a monoclonal antibody targeting IL-1β, reduced ischemic events in patients being treated for secondary prevention. Cellular, animal, and now clinical studies have suggested a role for therapies aimed at IL-1β for treatment of CAD. However, given potential side effects and costs of these medications, further study is required to determine which patients may be most suited for treatment above current standard of care.

22 Review 2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. 2018

Mehta, Shamir R / Bainey, Kevin R / Cantor, Warren J / Lordkipanidzé, Marie / Marquis-Gravel, Guillaume / Robinson, Simon D / Sibbald, Matthew / So, Derek Y / Wong, Graham C / Abunassar, Joseph G / Ackman, Margaret L / Bell, Alan D / Cartier, Raymond / Douketis, James D / Lawler, Patrick R / McMurtry, Michael S / Udell, Jacob A / van Diepen, Sean / Verma, Subodh / Mancini, G B John / Cairns, John A / Tanguay, Jean-François / Anonymous921134. ·McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. Electronic address: smehta@mcmaster.ca. · University of Alberta and Mazankowski Alberta Heart Institute, Edmonton, Alberta, Canada. · University of Toronto and Southlake Regional Health Centre, Toronto, Ontario, Canada. · Université de Montréal and Institut de Cardiologie de Montréal, Montréal, Quebec, Canada. · Royal Jubilee Hospital, University of British Columbia, Victoria, British Columbia, Canada. · McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada. · University of Ottawa Heart Institute, Ottawa, Ontario, Canada. · University of British Columbia and Vancouver General Hospital, Vancouver, British Columbia, Canada. · University of Toronto, Toronto, Ontario, Canada. · McMaster University and St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada. · University of Toronto and Women's College Hospital and Peter Munk Cardiac Centre of Toronto General Hospital, Toronto, Ontario, Canada. · University of Toronto and St Michael's Hospital, Toronto, Ontario, Canada. · Université de Montréal and Institut de Cardiologie de Montréal, Montréal, Quebec, Canada. Electronic address: jean-francois.tanguay@icm-mhi.org. ·Can J Cardiol · Pubmed #29475527.

ABSTRACT: Antiplatelet therapy (APT) has become an important tool in the treatment and prevention of atherosclerotic events, particularly those associated with coronary artery disease. A large evidence base has evolved regarding the relationship between APT prescription in various clinical contexts and risk/benefit relationships. The Guidelines Committee of the Canadian Cardiovascular Society and Canadian Association of Interventional Cardiology publishes regular updates of its recommendations, taking into consideration the most recent clinical evidence. The present update to the 2011 and 2013 Canadian Cardiovascular Society APT guidelines incorporates new evidence on how to optimize APT use, particularly in situations in which few to no data were previously available. The recommendations update focuses on the following primary topics: (1) the duration of dual APT (DAPT) in patients who undergo percutaneous coronary intervention (PCI) for acute coronary syndrome and non-acute coronary syndrome indications; (2) management of DAPT in patients who undergo noncardiac surgery; (3) management of DAPT in patients who undergo elective and semiurgent coronary artery bypass graft surgery; (4) when and how to switch between different oral antiplatelet therapies; and (5) management of antiplatelet and anticoagulant therapy in patients who undergo PCI. For PCI patients, we specifically analyze the particular considerations in patients with atrial fibrillation, mechanical or bioprosthetic valves (including transcatheter aortic valve replacement), venous thromboembolic disease, and established left ventricular thrombus or possible left ventricular thrombus with reduced ejection fraction after ST-segment elevation myocardial infarction. In addition to specific recommendations, we provide values and preferences and practical tips to aid the practicing clinician in the day to day use of these important agents.

23 Review HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology. 2018

Rosenson, Robert S / Brewer, H Bryan / Barter, Philip J / Björkegren, Johan L M / Chapman, M John / Gaudet, Daniel / Kim, Daniel Seung / Niesor, Eric / Rye, Kerry-Anne / Sacks, Frank M / Tardif, Jean-Claude / Hegele, Robert A. ·Cardiometabolics Unit, Icahn School of Medicine at Mount Sinai, Hospital Box 1030, One Gustave L. Levy Place, New York, New York 10029, USA. · Medstar Heart and Vascular Institute, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010, USA. · School of Medical Sciences, Faculty of Medicine, Level 4E, Wallace Wurth Building, University of New South Wales Sydney, 18 High Street, Sydney, Kensington New South Wales 2052, Australia. · Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, New York 10029, USA. · Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institutet, Karolinska Universitetssjukhuset, 171 77 Huddinge, Sweden. · National Institute for Health and Medical Research (INSERM) and Endocrinology Metabolism Service, Pitie-Salpetriere University Hospital, 83 Boulevard de l'Hôpital, 75651 Paris, France. · Lipidology Unit, Community Genomic Medicine Centre and ECOGENE-21, Department of Medicine, Université de Montréal, 930 Jacques-Cartier, Saguenay, Québec G7H 7K9, Canada. · University of Michigan School of Public Health, M4045 SPH II, 1415 Washington Heights, Ann Arbor, Michigan 48109-2029, USA. · Hartis-Pharma Sàrl, 13c Chemin de Bonmont, 1260 Nyon, Switzerland. · Nutrition Department, Harvard T. H. Chan School of Public Health, 665 Huntington Avenue, Boston, Massachusetts 02478, USA. · Montreal Heart Institute, Université de Montréal, 5000 Belanger Street, Montréal, Québec H1T 1C8, Canada. · Department of Medicine and Robarts Research Institute, Western University, 4288A-1151 Richmond Street North, London, Ontario N6A 5B7, Canada. ·Nat Rev Cardiol · Pubmed #28795686.

ABSTRACT: Plasma levels of HDL cholesterol (HDL-C) predict the risk of cardiovascular disease at the epidemiological level, but a direct causal role for HDL in cardiovascular disease remains controversial. Studies in animal models and humans with rare monogenic disorders link only particular HDL-associated mechanisms with causality, including those mechanisms related to particle functionality rather than cholesterol content. Mendelian randomization studies indicate that most genetic variants that affect a range of pathways that increase plasma HDL-C levels are not usually associated with reduced risk of cardiovascular disease, with some exceptions, such as cholesteryl ester transfer protein variants. Furthermore, only a fraction of HDL-C variation has been explained by known loci from genome-wide association studies (GWAS), suggesting the existence of additional pathways and targets. Systems genetics can enhance our understanding of the spectrum of HDL pathways, particularly those pathways that involve new and non-obvious GWAS loci. Bioinformatic approaches can also define new molecular interactions inferred from both large-scale genotypic data and RNA sequencing data to reveal biologically meaningful gene modules and networks governing HDL metabolism with direct relevance to disease end points. Targeting these newly recognized causal networks might inform the development of novel therapeutic strategies to reduce the risk of cardiovascular disease.

24 Review Orbital atherectomy for the treatment of severely calcified coronary lesions: evidence, technique, and best practices. 2017

Shlofmitz, Evan / Martinsen, Brad J / Lee, Michael / Rao, Sunil V / Généreux, Philippe / Higgins, Joe / Chambers, Jeffrey W / Kirtane, Ajay J / Brilakis, Emmanouil S / Kandzari, David E / Sharma, Samin K / Shlofmitz, Richard. ·a Division of Cardiology , Columbia University Medical Center , New York , NY , USA. · b Cardiovascular Research Foundation , New York , NY , USA. · c Department of Clinical and Scientific Affairs , Cardiovascular Systems, Inc. , St. Paul , MN , USA. · d Division of Cardiology , UCLA Medical Center , Los Angeles , CA , USA. · e Duke Clinical Research Institute , Durham , NC , USA. · f Morristown Medical Center , Morristown , NJ , USA. · g Hôpital du Sacré-Coeur de Montréal , Université de Montréal , Montréal , Canada. · h Department of Engineering , Cardiovascular Systems, Inc ., St. Paul , MN , USA. · i Metropolitan Heart and Vascular Institute , Mercy Hospital , Minneapolis , MN , USA. · j Minneapolis Heart Institute , Abbott Northwestern Hospital , Minneapolis , MN , USA. · k Piedmont Heart Institute , Atlanta , GA , USA. · l Division of Cardiology , Mount Sinai Hospital , New York , NY , USA. · m Department of Cardiology , St. Francis Hospital-The Heart Center , Roslyn , NY , USA. ·Expert Rev Med Devices · Pubmed #28945162.

ABSTRACT: INTRODUCTION: The presence of severe coronary artery calcification is associated with higher rates of angiographic complications during percutaneous coronary intervention (PCI), as well as higher major adverse cardiac events compared with non-calcified lesions. Incorporating orbital atherectomy (OAS) for effective preparation of severely calcified lesions can help maximize the benefits of PCI by attaining maximal luminal gain (or stent expansion) and improve long-term outcomes (by reducing need for revascularization). Areas covered: In this manuscript, the prevalence, risk factors, and impact of coronary artery calcification on PCI are reviewed. Based on current data and experience, the authors review orbital atherectomy technique and best practices to optimize lesion preparation. Expert Commentary: The coronary OAS is the only device approved for use in the U.S. as a treatment for de novo, severely calcified coronary lesions to facilitate stent delivery. Advantages of the device include its ease of use and a mechanism of action that treats bi-directionally, allowing for continuous blood flow during treatment, minimizing heat damage, slow flow, and subsequent need for revascularization. The OAS technique tips reviewed in this article will help inform interventional cardiologists treating patients with severely calcified lesions.

25 Review Implications of GLAGOV study. 2017

Nicholls, Stephen J / Puri, Rishi. ·aSouth Australian Health and Medical Research Institute bUniversity of Adelaide, Australia cQuébec Heart & Lung Institute, Québec, Canada dCleveland Clinic Coordinating Center for Clinical Research, Cleveland, Ohio, USA. ·Curr Opin Lipidol · Pubmed #28937411.

ABSTRACT: PURPOSE OF REVIEW: Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition has emerged as a novel approach to lowering levels of low-density lipoprotein cholesterol (LDL-C). The impact of PCSK9 inhibition in statin-treated patients on coronary atherosclerosis had remained unknown. RECENT FINDINGS: The GLAGOV trial compared the effect of the PCSK9 inhibitor, evolocumab, and placebo on progression of coronary atherosclerosis in patients treated with at least moderate intensity statin therapy. Predictable lowering of LDL-C with evolocumab (36.6 versus 93.0 mg/dl) associated with significant regression of coronary atherosclerosis. A direct relationship was observed between achieved LDL-C levels and disease progression. SUMMARY: Addition of evolocumab to statin therapy produces incremental regression of plaque regression in patients with established coronary artery disease. This finding provides a biological rationale for the reported beneficial effects of evolocumab on cardiovascular events.

Next